Phase I Dose-Escalation Study of Stereotactic Body Radiotherapy in Patients With Hepatic Metastases

scientific article published on 03 November 2010

Phase I Dose-Escalation Study of Stereotactic Body Radiotherapy in Patients With Hepatic Metastases is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1009188947
P356DOI10.1245/S10434-010-1405-5
P953full work available at URLhttp://link.springer.com/content/pdf/10.1245/s10434-010-1405-5.pdf
http://www.annalssurgicaloncology.org/cgi/content/abstract/18/4/1081
http://link.springer.com/article/10.1245/s10434-010-1405-5/fulltext.html
http://link.springer.com/content/pdf/10.1245/s10434-010-1405-5
P698PubMed publication ID21046264

P2093author name stringLiyue Tong
Robert Timmerman
Jeffrey Meyer
Ramzi Abdulrahman
Paul Weatherall
Thomas Boike
William Rule
L. Chinsoo Cho
Roderich E. Schwarz
P2860cites workUniversal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapyQ40014973
Surgical treatment of colorectal metastases to the liverQ40559150
Analysis of radiation-induced liver disease using the Lyman NTCP model.Q44048914
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trialQ44306113
Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trialQ44586518
Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancerQ48151239
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastasesQ49186620
Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial.Q52142739
Optimization of radiation therapy II: the critical-voxel model.Q52693730
An overview of hypofractionation and introduction to this issue of seminars in radiation oncology.Q53133028
Interim analysis of a prospective phase I/II trial of SBRT for liver metastases.Q53519999
Radiofrequency Ablation of 100 Hepatic Metastases with a Mean Follow-Up of More Than 1 YearQ60629797
Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patientsQ71783537
Resection of colorectal liver metastasesQ72216092
Ultrasound-guided percutaneous alcohol injection of small liver metastases. Results in 40 patientsQ72736695
Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinomaQ74081538
Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patientsQ74543135
Stereotactic radiotherapy of targets in the lung and liverQ77483854
Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastasesQ79465276
Stereotactic radiotherapy of primary liver cancer and hepatic metastasesQ80282837
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastasesQ80394070
[Stereotactic radiation therapy for liver metastases]Q81721571
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastasesQ83412928
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Q28131668
Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions).Q31117028
Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignanciesQ33382057
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive casesQ33874670
Stereotactic body radiation therapy for inoperable early stage lung cancerQ34010065
Trends in long-term survival following liver resection for hepatic colorectal metastasesQ34523502
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastasesQ34557044
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancerQ34575077
Cryotherapy in the treatment of liver metastases from colorectal cancerQ34598668
A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesionsQ34723820
Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective resultsQ36678756
Stereotactic body radiation therapy in multiple organ sitesQ36756959
Surgical therapy for colorectal metastases to the liverQ36832322
Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?Q36956302
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectdose fractionationQ5299253
P304page(s)1081-1087
P577publication date2010-11-03
P1433published inAnnals of Surgical OncologyQ2853069
P1476titlePhase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases
Phase I Dose-Escalation Study of Stereotactic Body Radiotherapy in Patients With Hepatic Metastases
P478volume18

Reverse relations

cites work (P2860)
Q36415438A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases
Q39415601A single reference measurement can predict liver tumor motion during respiration
Q48492687Clinical experience with planning, quality assurance, and delivery of burst-mode modulated arc therapy
Q37308725Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).
Q36945323Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases
Q87893313Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases
Q34655878Current and emerging treatment options for uveal melanoma
Q35782954Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection
Q27015651Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice
Q61054503Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer
Q92315128High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases
Q50324017Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy
Q40395624Local ablative radiotherapy of oligometastatic colorectal cancer
Q33645887Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients
Q30415022Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements
Q35905087Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions
Q89481572MRI-guided adaptive radiotherapy for liver tumours: visualising the future
Q91675162Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
Q34974386Minimally invasive local therapies for liver cancer
Q26744490Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation
Q33779859Multidisciplinary approach of colorectal cancer liver metastases
Q38091331Oligometastases: the new paradigm and options for radiotherapy. A critical review
Q26828767Oligometastasis and oligo-recurrence: more than a mirage
Q50650651Optimization of stereotactic body radiotherapy treatment planning using a multicriteria optimization algorithm.
Q37458034Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma
Q38685466Radiobiology of stereotactic body radiation therapy (SBRT).
Q26864247Review and uses of stereotactic body radiation therapy for oligometastases
Q37708013Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer
Q36383996Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors
Q64094411Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases
Q60957976Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study
Q37048588Single-dose radiosurgical treatment for hepatic metastases--therapeutic outcome of 138 treated lesions from a single institution
Q49787609Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry
Q39598540Stereotactic ablative radiotherapy for oligometastatic disease in liver
Q90478112Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when?
Q36360066Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review.
Q35971469Stereotactic body radiation therapy for liver metastases from colorectal cancer: analysis of safety, feasibility, and early outcomes
Q50355067Stereotactic body radiation therapy for liver metastasis - The linac-based Greater Poland Cancer Centre practice
Q33919725Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors
Q21129307Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors
Q33769424Stereotactic body radiation therapy using the CyberKnife(®) system for patients with liver metastases
Q87499954Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy
Q37152196Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions.
Q58790310Stereotactic body radiotherapy using the CyberKnife system in the treatment of patients with liver metastases: state of the art
Q38175120Stereotactic body radiotherapy: a critical review for nonradiation oncologists
Q35731820Stereotactic radiation therapy for liver metastases: factors affecting local control and survival
Q50061872Strategies for prediction and mitigation of radiation-induced liver toxicity.
Q33706721Strategies to tackle the challenges of external beam radiotherapy for liver tumors
Q92372917Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?
Q32173610Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer.
Q92725532Technical Assessment of an Automated Treatment Planning on Dose Escalation of Pancreas Stereotactic Body Radiotherapy
Q37878852The role of local therapy in the management of lung and liver oligometastases.
Q39371182Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer
Q38191920Treatment of metastatic liver tumors using stereotactic ablative radiotherapy